Alcohol and Drug Abuse Research Center
Center for Depression, Anxiety and Stress Research
McLean Imaging Center
Clinical Unit Based Research
Mailman Research Center
Shervert H. Frazier Research Institute
Clinical Trials
Inventions for License
Research News


MCL 187.0: Treatment of Mental Conditions Including Depression

Perry Renshaw, M.D., Ph.D.

Background and Description

The invention is based on the discovery that patients suffering from depression have decreased levels of adenosine in the brain. This leads to the hypothesis that disorders like depression, schizophrenia, etc. can be treated by agents that cause increased levels of adenosine in the brain.

Potential Commercial Uses

The invention comprises a method of treating disorders like depression, by administering a compound that can inhibit uptake of adenosine, which inhibits its breakdown in the brain, or which supplies or releases the compound. In addition to depression, the invention may be useful for treatment of bipolar disorder, manic depression, schizophrenia, or substance abuse.

Publication and Patent Status

McLean Hospital is the owner of U.S. Patent Number 6,258,794 claiming this invention. (USPTO # 6,258,794)

Licenses Available

McLean Hospital is offering a worldwide exclusive license to this technology.

For more information, please contact:

David J. Glass, Ph.D.
Senior Associate Director, Technology Transfer
McLean Hospital Research Administration
115 Mill Street
Belmont, MA 02478-9106
(617) 855-3825 - tel
(617) 855-3745 - fax